Source: DGNews  |  Posted 8 years ago

By Maury M. Breecher, PhD, MPH

SAN DIEGO, CA -- May 21, 2003 -- Repaglinide monotherapy was significantly more effective than nateglinide monotherapy for reducing hemoglobin A1c (HbA1c), and fasting plasma glucose (FPG) levels in patients with type 2 diabetes, according to a multicenter trial.

Results were presented on May 16th here at the American Association of Clinical Endocrinologists 12th Annual Meeting and Clinical Congress.

One hundred and forty patients took part in this 16-week, open-label, randomized, parallel-group study. Participants started with HbA1c values between 7% and 12% during a previous treatment of diet and exercise alone.

Both repaglinide and nateglinide had similar postprandial glycemic effects, but repaglinide monotherapy at a final dose of 6 mg/day, was clinically and statistically more effective than nateglinide monotherapy at a final dose of 360 mg/day, in reducing FPG and HbA1c values, according to lead study author Mohammed F. Saad, MD, Los Angeles Diabetes Center, Alhambra, Calif.

The 71 patients on repaglinide started with a baseline HbA1c of 8.9%, and had a mean change of